fda semaglutide news approves first-ever oral GLP-1RA for obesity and chronic weight management. Meet Wegovy (semaglutide) tablets. https://www.prnewswire.com/ news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults FDA: Novo Nordisk's Ozempic and

While other medications, like phentermine and orlistat, have been used for weight management

No pharmacological stack is clinically recommended or UK-endorsed for retatrutide, as it remains an investigational agent without MHRA marketing authorisation, restricted to regulated clinical trials

Ongoing research is probing novel applications of GLP-1 agonists beyond diabetes and obesity from potential use in metabolic dysfunction-associated steatohepatitis (MASH) to trials investigating neuroprotective effects in conditions like Parkinsons and Alzheimers disease, though the 2025 phase 3 trials in both conditions failed to show clinical benefit ( [24] ) ( [25] )

EGT was also demonstrated to play no role in protecting mycelia from cupric oxide toxicity

Currently, semaglutide is considered one of the most effective anti-obesity interventions, with some scientists describing the United States Food and Drug Administration (FDA) approval of this drug as a "paradigm shift" in anti-obesity treatment